Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Search Seller Projects – ,
Middle East: Israel
Israeli cancer treatment center seeks investment.
The Israeli cancer treatment center has a project which specializes in the development and commercialization of innovative in vitro cancer diagnostic products and solutions. The product portfolio includes the latest technologies involving gene expression, biomarkers, and histochemical analysis for early cancer detection and personalized medicine. The project provides proprietary diagnostic solutions for a variety of cancer diagnostic applications and practical answers to unmet practical needs. The center seeks investment.
Middle East: Israel
Israeli medical company seeks investment.
The Israeli medical company has a product that is a microemulsion composed of phospholipids and triglycerides. It can form a tear film like elastic lipid shield to improve vision. It is a CE-certified III drug. Project is designated for post-operative ophthalmic surgery (e.g., refractive surgery, cataract surgery, and corneal transplantation), corneal erosion, and dry eye syndrome. This product is the only product on the eye drops market with clinical evidence that corneal epithelium thickens again after mechanical, traumatic, and surgical epithelial loss. As a microemulsion carrier, the technology can be used as a drug delivery platform in the pre-clinical stage. Its unique pharmaceutical advantages include a longer contact time between drug and eye surface which can increase compliance. The company seeks investment.
Middle East: Israel
Israeli medical equipment company seeks investment.
The Israeli medical equipment company has a solution for outpatient ophthalmology departments, which can control the release of ophthalmic drugs over time, so as to solve the problem of inaccurate eye drop dispensing, enabling patients to 100% comply with the drug treatment plan. The device can be applied to the most prescribed glaucoma drugs. The product has completed a clinical study under the regulatory pathway procedure of FDA 505 (b) (2) as part of the application of new drugs. The goal of the company is to further develop the platform to treat other eye diseases. At present, the company seeks investment for its next step.
Middle East: Israel
Israeli medical equipment company seeks investment.
The Israeli medical equipment company created a pulmonary edema monitor (non-invasive) device. Pulmonary effusion is the main cause of decompensation and hospitalization of heart failure. The determination of pulmonary effusion in the first stage is crucial. Otherwise, the treatment effect is poor. Since the lung is a chest organ, it is difficult to measure the amount of pulmonary effusion in the first stage. The new device based on the new patented technology can distinguish the fluid of the whole chest from the fluid of the lungs. Compared with the existing device, this method improves the sensitivity of measuring lung fluid by 25 times. The device has high predictive sensitivity for hospitalization of heart failure (98%), can determine very small changes in lung fluid and start preventive treatment early in the decompensation of heart failure. Some studies using the device have found that the use of the device in the hospital can greatly shorten the length of hospital stay and improve the mortality in the hospital and after discharge. Home care using the device showed a 65% reduction in the number of hospitalizations and a 60% reduction in mortality. At present, the company seeks investment.
Middle East: Israel
Israeli medical company seeks investment.
The respiratory medical company in Israel has developed a medical device for the treatment of COPD (chronic obstructive pulmonary disease). The mission is to alleviate the suffering of critically ill patients with COPD. The device is a non-invasive pressure pulse generator. Its unique pressure wave and frequency make it a super unique and effective method to open the airway of pulmonary collapse in COPD. At present, the company seeks investment.
Middle East: Israel
Israeli medical company seeks market expansion.
The Israeli company holds 24 patents with new and innovative medical devices. The company has been approved by FDA and CE. The company develops and targets minimally invasive cryoablation therapy for women's health and interventional oncology (kidney cancer, lung cancer, liver cancer, bone cancer, and prostate cancer). The system provides outpatient definitive treatment for breast tumors and ablation of other cancerous tumors in the body. Clinical trials have been completed in Europe, America, and Japan. In Europe, Latin America, Asia, and other markets, initial sales are around USD 500 million. The company also targets breast cancer markets. The goal of the company is to seek investment for market expansion.
Middle East: Israel
Isreali cancer treatment company seeks investment
The Israeli cancer treatment company is developing a new biological / drug platform (NADAV technology) - a proprietary strain based on oncolytic virus NDV, which can target a variety of cancers. A series of in vivo, in vitro and clinical studies on NDV strains, show that NDV strains retain the potential selective and targeted cell death (apoptosis) mechanism of human cancer cells. Another virus named Mucus virus can preferentially replicate and kill cancer cells. For the virus to have oncolytic effect, it must be safe for human beings, only kill cancer cells while retaining normal cells, and genetic stability. The company seeks investment.
Middle East: Israel
Israeli R&D medical equipmet company seeks strategic partners and investment.
The Israeli R&D medical equipment company has developed a unique lockable fixation technology for soft tissue repair, which fixed implants will not be displaced by existing nails. The project which has been successfully launched is the first and only fixation solution like suture. The permanent version has been put on the market, and the absorbable products will be available soon. While commercializing, the team is also studying suture-based fixation solutions through the patents it has. Robotic surgery is the current trend, and these solutions can support robotic suture such as cardiovascular surgery. The company's financial return is very high: it has complete manufacturing capacity and has been successfully started, and its current revenue has exceeded USD 550,000. The company's goal is to obtain FDA approval for suture-based products and interact with strategic partners.
Asia: Israel
Israeli medical company seeks investment.
The Israeli medical company has developed a surface cryotherapy equipment and system, which can be inserted into the bladder through a cystoscope (endoscope) to visualize the interior of the bladder. Surface cryotherapy is a potential paradigm shift in the treatment of superficial bladder cancer. The reaction of the tissue to the frozen spray can be seen in real-time so that the therapist can assess the destruction of the tissue in real-time and has excellent visualization in all operative stages. The project adopted a new method for treating superficial bladder cancer. It uses surface cryotherapy, which uses extreme cold to freeze and destroy abnormal tissues. Its minimally invasive solution for non-muscle invasive bladder cancer (NMIBC) provides outpatient treatment options for surgery. The company announced that their cryoablation for bladder cancer has made a successful preclinical trial. The company seeks investment for next coming steps.
Asia: Israel
Israeli geriatric care company seeks investment.
The Israeli geriatric care company is developing products aimed at aging. The product is a patented device for making the pill into a delicious gel, which is a movable container with gel inside. The device requires a small disposable glass in which the pill is crushed, and the patient takes the gel. This process only takes 14 seconds. The device will allow patients, especially those with swallowing problems, to receive the pills in a safe and tasty way. The device will be suitable for medical facilities, as well as private customers who care for the elderly at home. The company plans to use this phase of funding to build prototypes of the device and glass, and then build a working model that could be used to mass-produce drug tests. At the same time, the firm will prove the safety of the gel, pursue the patented development on glass. The project has POCs in gel safety, device patents, business plans, and regulatory strategies. The product is scheduled for launch after FDA approval in 2021.
Asia: Israel
Israeli biomedicine R&D company seeks investment.
The Israeli biomedicine R&D company has a project which has been developed and patented. This project aims to reduce the resistance of tumor to conventional treatment. Several diagnostic tests were used to decipher the specific tumor metabolic addiction profile (STMAP), considering the essential nutrients required for tumor proliferation and growth, and the tumor microenvironment profile (TMEP), the cellular environment in which the tumor exists. In addition, the project uses metabolic biomarkers to understand the molecular and cellular mechanisms driving tumor initiation, maintenance and expansion, combined with predictive (diagnostic) metabolic biomarkers to assist in matching targeted therapies (drugs and natural compounds). The company seeks investment for this project.
Asia: Israel
Israeli medical AI imaging company seeks $1.7 million investment.
The Israeli medical AI imaging company is developing a portable real-time diagnostic system, which can be operated by non-experts at first aid, remote areas, medical centers, military, and hospital beds. Lower prices than advanced imaging systems allow products to be more widely spread. The product is a combination of hardware (RF) products and software (AI), which has been proved to be physically feasible. The company has worked with doctors in several hospitals and passed the review of innovation by the Sheba Medical Center. The technology-based on harmless mobile phone RF radiation and non-imaging artificial intelligence runs on local hardware and can be wirelessly connected to hospital equipment. The company seeks investment for $1.7 million at least, as it is the base required to complete the POC of patient data for clinical trials.
Enquire for more information about our services, and how we can help solve challenges for your organization
Contact Us